Product Description
Dihydrocodeine is a synthetic opioid analgesic developed in the early 1900s. Its structure and pharmacokinetics are similar to that of codeine and it is used for the treatment of postoperative pain or as an antitussive. It is becoming increasingly important to assess the relative efficacy and harm caused by different treatments. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176625/)
Mechanisms of Action: OPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Bulgaria | Colombia | Cyprus | Czech | Estonia | France | Germany | Hong Kong | Hungary | Ireland | Korea | Latvia | Malaysia | Malta | New Zealand | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Switzerland | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|